What Has Been the Growth Trajectory for the Oligonucleotide Synthesis Market in Recent Years?
The oligonucleotide synthesis market has seen considerable growth due to a variety of factors.
•The market size for oligonucleotide synthesis has seen significant expansion in the past few years. The projection of its growth is from $10.33 billion in 2024 to $11.94 billion in 2025, displaying a compound annual growth rate (CAGR) of 15.6%.
Factors contributing to the growth during the historic period include advancements in biomedical research, the progress of therapeutic development, novel biotechnology innovations, increased focus on genomic studies, and a rise in DNA technologies.
How Does the Forecast Look for the Oligonucleotide Synthesis Market?
The oligonucleotide synthesis market is expected to maintain its strong growth trajectory in upcoming years.
• The market for oligonucleotide synthesis is projected to witness substantial growth in the coming years, increasing to $22.29 billion by 2029 with a CAGR of 16.9%.
This expected growth within the prediction period is likely due to the emergence of novel diagnostic tools, RNA interference (RNAi) treatments, regenerative medical practices, nanotechnology uses, and strides made in gene editing. Key trends expected within this forecasted period encompass focused drug development, creative delivery systems, automated synthesis processes, the utilization of CRISPR-cas technology, and advancements in next-generation sequencing (NGS).
What Are the Critical Driver Fuelling the Oligonucleotide Synthesis Market's Growth?
The increase in chronic illnesses is anticipated to fuel the expansion of the oligonucleotide synthesis market. Chronic illnesses are characterized by their duration of a year or more and the need for ongoing medical care, with a tendency to become more severe over time. Oligonucleotides influence gene expression, leading to chronic diseases through various pathways. These can target mRNA, pre-mRNA, or non-coding RNA to alter splicing events, initiate degradation, or interrupt protein translation. For example, in September 2022, the World Health Organization, a Switzerland-based agency of the United Nations, reported 41 million deaths, constituting 74% of the total global deaths caused by non-communicable diseases (NCDs) or chronic illnesses per year. Cardiovascular diseases were responsible for 17.9 million deaths, cancer for 9.3 million, chronic respiratory diseases for 4.1 million, and diabetes for 2.0 million. Thus, the growing prevalence of chronic and uncommon diseases is propelling the oligonucleotide synthesis market's progress.
How Is the Oligonucleotide Synthesis Market segmented?
The oligonucleotide synthesis market covered in this report is segmented –
1) By Type: Custom Oligos, Predesigned Oligos
2) By Product Type: Oligonucleotides, Reagents, Equipment, Services, Purification, Modification
3) By Application: Therapeutic Applications, Research Applications, Diagnostic Applications
Subsegments:
1) By Custom Oligos: Long Oligonucleotides, Short Oligonucleotides, Modified Oligonucleotides
2) By Predesigned Oligos: Gene-Specific Oligos, Probe Oligos, Primers For PCR And RT-PCR
Pre-Book The Oligonucleotide Synthesis Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing the Oligonucleotide Synthesis Market?
The oligonucleotide synthesis market is seeing a rise in the trend of product innovation. To maintain their market stance, leading firms are bringing innovative products to the table. One such example is Ansa Biotechnologies, Inc., a company based in the US and renowned for manufacturing complex DNA. It introduced Ansa Clonal DNA and Ansa DNA Fragments in July 2024. The former provides clonal and sequence-perfect DNA up to a length of 600 base pairs. This eliminates the requirement for assembly, thereby ensuring unparalleled precision in intricate synthetic biology projects. The product promises error-free and ready-to-use DNA sequences, making it a trustworthy choice for researchers. Ansa DNA Fragments, on the other hand, offer sequence-verified linear double-stranded DNA fragments, up to 600 base pairs, customized for a variety of research uses. Leveraging its advanced enzymatic synthesis process, Ansa persistently delivers complex DNA constructs, which consist of repeats and secondary structures, with a high degree of accuracy.
Who Are the Key Players in the Oligonucleotide Synthesis Market?
Major companies operating in the oligonucleotide synthesis market include:
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Merck KGaA
• GE HealthCare Technologies Inc.
• Eurofins Scientific SE
• Agilent Technologies Inc.
• Nitto Denko Avecia Inc.
• Alnylam Pharmaceuticals Inc.
• Maravai Life Sciences
• LGC Limited
• Ionis Pharmaceuticals Inc.
• GenScript Inc.
• Ajinomoto Bio-Pharma Services
• Sarepta Therapeutics Inc.
• Integrated DNA Technologies Inc.
• Twist Bioscience Corporation
• Eurogentec SA
• Kaneka Eurogentec S.A.
• Biocomma Limited
• Bio-Synthesis Inc.
• TriLink BioTechnologies Incorporated
• Generi Biotech s.r.o.
• ATDBio Ltd.
• BioAutomation Corporation
• Biolegio B.V.
• Dharmacon Research Inc.
What Is The Most Dominant Region In The Oligonucleotide Synthesis Market?
North America was the largest region in the oligonucleotide synthesis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oligonucleotide synthesis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
